CLRB Cellectar Biosciences Inc

$CLRB The data is more than amazing and they will show you the potential that it has with multiple indications that they have studied this on with the clover 1 study. Roughly 10 years of data. Multiple CR lasting over 5 years. We are talking zero other treatments available and they have a CR for years. They big reveal and true story will come out soon

$CLRB Cellectar Biosciences (NASDAQ: CLRB) published a case study describing a complete response lasting more than eight years in a patient with diffuse large B-cell lymphoma (DLBCL) treated with a single administration of iopofosine I 131.

$CLRB The price action is baffling to say the least. After getting absolutely shredded, I would love to see this gap up and catch the market off guard.

$CLRB details a durable 8-year complete response in a DLBCL patient after a single iopofosine I-131 dose.

$CLRB • Blockbuster Efficacy: Exceptional 79.2% MRR in post-BTKi patients beats the global 61.8% baseline.🚀 • Deepening Responses: High probability of hitting ≥33% CR/VGPR on Oct 15 as data matures.🚀 • Massive Upside: Wall Street targets $11.50+, offering over 600% potential gains from $1.57.🚀 • Imminent Approval: Regulatory path clears the way for an FDA submission in mid-2027.🚀 • Takeover Target: Absurdly low $15.8M market cap makes it a prime acquisition for Big Pharma.🚀

$CLRB next catalyst, cr an pvcr of post btki cohorte (24 patients). If its around 30%, that would be crazy fantastic. 2nd line then almost 100% certain. 15. octobter 🍀🍀🚀🚀🚀🚀🚀🚀

$CLRB Iopofosine I-131 in post-BTKi Waldenström’s macroglobulinemia. The difficult-to-treat group achieved a 100% ORR clinical benefit rate and 87.5% MRR overall response rate. The median duration of response lasted 16 to 18 months. An NDA submission for FDA and EMA approval is planned for H1 2027. 🍀🍀🚀🚀🚀🚀

$CLRB If leadership is reading these posts, would you consider removing the “combined years of experience” slide from your future presentations? This data is immaterial if it does not translate into shareholder value creation. In the absence of results against your own “Formula for Value Creation”, highlighting decades of collective experience risks inviting ridicule rather than inspiring confidence.

$CLRB if the insiders don’t support this stock with market buys and management neither am I. Almost time to harvest this for tax season next year.

$CLRB I raised this earlier: Nantahala led the oversubscribed offering and secured a board seat. Did Jim effectively open the door to a short selling strategy by signing off on this structure or is this all theatrics ahead of a major partnership or acquisition? Both are speculative.

$CLRB slowly loading today looking to swing. Can't go straight down forever, and no urgent dilution necessary with all the cash they have on balance sheet.

$CLRB glad I bought spacex. Management needs to address this issue. Always delays and dilution. Not buying anymore of this pos either way. May even sell. It’s clear that they don’t care about the shareholders.

$CLRB $ 1.46 😆 another reverse split in making. Try to short this pig 🐖 @ $ 3.00. Its said you need extra margin for this. Only people make money out of this bio scams are people who run this kind of scam and brokers. Stay away.....

This guy called AIOK and it went parabolic! He's been on fire Make sure to give a Follow. Actually a decent trader 🔥💯 $CLRB $SRPT $IFRX $NKE Great dip buys here

$CLRB I came up with the gut feeling they might be announcing a global partnership soon, after stretching it long enough to see if they could license it regionally in EU and dropped it at the very end. Just my gut feeling.

$CLRB clover-1 study and pediatric study all using clr-131 ended in May. They have shared bits of details including multiple CR is all indications they studied. I believe we see that updated data in December at ASH. We should also see the updated TNBC data that management has said multiple times they are very encouraged with in December as well. This all leads going into JPM conference and hopefully announcing during that conference that they dosed 1st patient and will be submitting NDA for accelerated approval.

$CLRB Upcoming & Recent 2026 Conferences / Events • International Workshop for Waldenström Macroglobulinemia • Date: October 15, 2026 (4:00 PM PDT) • Location: Palm Springs, CA • Details: Presenting efficacy data from the Phase 2 CLOVER WaM subset analysis of iopofosine I 131 in patients refractory or resistant to BTK inhibitor

$CLRB it's a bit weird. It seems like the EMA submission in now dependant on the US submission, that is, it's now a second lien matter. At least this is what I gathered from the October corporate presentation. If that is correct, all future warrants are tied only to US milestones.

$CLRB trial end In may. The clr 131 trial results could maybe be released? You know the whole mechanism thing. Same with the ped program ended in may. Another clr 131 thing…

$CLRB the co. needs to sign that partnership good or bad. It can't go alone and doesn't have the necessary expertise to commercialize ipofosine. Plus, it's about time to focus work on the rest of the pipeline.